Business, energy, technology, markets and global industry news from Business News Today

BE BOLD

PharmaDeviceNews BE BOLD
A molecular illustration of antibody activity highlights argenx SE’s $2.2 billion acquisition of Forte Biosciences and the addition of investigational anti-CD122 antibody FB102 to its immunology pipeline. Representative image.
Pharma & Biotech

BIMZELX beat AbbVie’s US$5.8bn-a-quarter SKYRIZI on joint response. Why UCB still cannot claim broad superiority

BIMZELX sustained higher ACR50 than SKYRIZI at Week 24, but UCB’s statistical hierarchy limits broader superiority claims.

Read More